Researchers examined the correlation between exposure to monotherapy with 10 different antiepileptic drugs in the first two months of pregnancy and the risk for 23 major congenital malformations.
A remote electrical neuromodulation (REN) device may offer a safe and effective non-pharmacologic alternative for acute migraine treatment.
In patients with prior myocardial infarction (MI)/ischemic stroke, treatment with alirocumab is associated with a reduction in LDL-C, as well as reductions in lipoprotein(a), apolipoprotein B, and non-HDL-C.
Simvastatin’s beneficial effects on clinical outcomes and brain atrophy in patients with multiple sclerosis (MS) are largely independent of cholesterol levels.
The FDA has approved an expanded indication for Emflaza (deflazacort; PTC Therapeutics, Inc.) to include children 2 to 5 years of age with Duchenne muscular dystrophy.
The FDA has expanded the approval of Lyrica (pregabalin; Pfizer) for pediatric patients 1 month of age and older as adjunctive therapy for the treatment of partial-onset seizures.
The FDA has granted Orphan Drug designation to CAD-1883 (Cadent Therapeutics), an investigational treatment for spinocerebellar ataxia (SCA).
Intravenous thrombolytics used between 4.5 to 9 hours after ischemic stroke onset or after waking with symptoms resulted in 0 to minimal neurologic deficits.
The investigators of this Phase 3 study sought to evaluate the efficacy and safety of ADS-5102 (amantadine) extended-release capsules to treat multiple sclerosis patients with walking impairment.
Study evaluates the benefits of ocrelizumab on 48-week confirmed disability progression in MS observed in pooled OPERA I and OPERA II, as well as a 3 year ocrelizumab treatment in an open-label extension.
